For effective targeting and inhibition of PD-1/PD-L1, with the goal of restoring an anti-tumor T cell response, a T cell must recognize a tumor antigen bound to major histocompatibility complex (MHC) proteins on an APC surface to become activated. The gene discussed is PDCD1; the disease is neoplasm.